Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

ACE-031 Dosage Protocol - Peptide Dosages

ACE-031 (1 mg) Dosage Protocol A soluble activin receptor type IIB (ActRIIB) Fc-fusion protein that traps myostatin and related muscle-limiting factors. Its clinical development was halted for safety. Research-use-only — this page is an educational reference a

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

ACE-031 (1 mg) Dosage Protocol

A soluble activin receptor type IIB (ActRIIB) Fc-fusion protein that traps myostatin and related muscle-limiting factors. Its clinical development was halted for safety. Research-use-only — this page is an educational reference and a caution, not a dosing recommendation.

Why ACE-031 draws research interest

These are the directions researchers and the peptide community most often explore ACE-031 for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

It blocks the body’s brake on muscle — the myostatin pathway

Myostatin (also called GDF-8) is a member of the TGF-β family that acts as a negative regulator of muscle growth: animals engineered to lack it develop dramatically enlarged, "double-muscled" physiques. ACE-031 exploits this by presenting a soluble copy of the receptor those factors bind to, soaking them up before they reach muscle. The underlying biology is real and well established, which is exactly why several different companies have chased myostatin-pathway drugs.

Trapping more than myostatin is a double-edged design

ACE-031 is built from ActRIIB, a receptor that binds not just myostatin but a family of related ligands (activins and other TGF-β proteins). That broad reach is part of why it produced larger muscle effects than selectively blocking myostatin alone — but it is also the most likely reason it caused problems outside muscle. Those same activin-family signals are important in blood vessels, and the bleeding-type side effects (nosebleeds, dilated small vessels) that stopped its trials are generally attributed to this off-target ligand blockade. Broad is powerful and risky at the same time.

The honest headline is the safety halt, not the muscle gain

It is easy to find the encouraging numbers — a few percent more lean mass after a single dose in an early study. The responsible reading foregrounds what happened next: in the trial that mattered most, in boys with Duchenne muscular dystrophy who genuinely needed a muscle therapy, the study was stopped before it could show benefit because of bleeding-related side effects. A compound abandoned by its developer for safety is not a "muscle builder" waiting to be rediscovered; it is a cautionary chapter in myostatin-drug development.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

Mix & measure ACE-031 · 1 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

A soluble ActRIIB-Fc decoy that traps myostatin (GDF-8) and related activin-family ligands, blocking the normal negative regulation of muscle mass. Because it captures multiple ligands — not myostatin alone — its effects are broader than selective myostatin inhibition, which is thought to underlie its off-target actions.

A discontinued investigational biologic, not a drug. It is not approved for human use and has no established dose. Its Duchenne muscular dystrophy trial was stopped early because participants developed nosebleeds and telangiectasias. Grey-market "ACE-031" vials are unverified and disconnected from any approved product.

A single subcutaneous dose increased lean and thigh-muscle mass in healthy postmenopausal women in a phase 1 study. In boys with Duchenne muscular dystrophy, only non-significant trends were seen before the study was halted for safety. Muscle biology is promising; this particular molecule was abandoned.

Quickstart Highlights

ACE-031 (research name ramatercept) is not a small peptide at all — it is a large fusion protein built from the extracellular, ligand-binding domain of the activin receptor type IIB (ActRIIB) fused to an antibody IgG1-Fc region[3]. It works as a soluble decoy receptor: released into the circulation, it mops up myostatin (GDF-8) and several related TGF-β-family proteins before they can reach the real receptors on muscle, releasing the brake those factors normally keep on muscle growth[2].

This page is an educational reference on what ACE-031 is, what its trials actually showed, and how a lyophilized research vial is reconstituted. It is not medical advice and not a protocol to administer the compound. The most important fact belongs at the top: ACE-031’s clinical program in Duchenne muscular dystrophy was stopped early for safety — participants developed nosebleeds (epistaxis) and dilated small blood vessels (telangiectasias), off-target effects that led the sponsor to discontinue the study[4]. ACE-031 is not FDA-approved, was never brought to market, and is documented here with that safety history front and center.

A soluble ActRIIB–IgG1-Fc fusion protein (ramatercept) that binds myostatin and related ligands, acting as a decoy receptor to promote muscle growth[2][3]. A large biologic, not a short peptide.

1 mL bacteriostatic water per 1 mg vial → 1 mg/mL. This is a lab-handling reference only; the site provides no dose for administration.

Not FDA-approved. Its Duchenne muscular dystrophy trial was stopped early for safety (epistaxis, telangiectasias) and the program was discontinued[4].

Early-phase human trials, then halted. A single-dose study in healthy women showed measurable muscle gains[1]; the DMD study was stopped for non-muscle safety concerns before efficacy could be established[4].

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Retinalamin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Retinalamin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02AHK-Cu — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. AHK-Cu is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Amycretin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04GHK (Copper-Free) — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. GHK (Copper-Free) is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
comparison

Comparison with Other Myostatin Inhibition Approaches in ALS Research

ACE-031 is one of several myostatin pathway inhibitors that have been investigated in ALS or related muscle-wasting contexts. Key comparators include: Anti-myostatin antibodies (landogrozum…

Source: peptideslabuk.com
Research context

Read sources and limitations before applying a claim.

Can I use ACE-031 as a research chemical if I can find it?

ACE-031 has never been approved for human use and clinical development was discontinued. Any product sold as ACE-031 is of unknown origin and quality. The compound is a complex fusion protein sensitive to degradation, making DIY sourcing extremely risky with high contamination likelihood.

Source: peptide-db.com ↗

Summary for Researchers

ACE-031 bone density research extends the compound’s primary myostatin-inhibition biology into skeletal biology through the shared ActRIIB ligand system that regulates both muscle and bone remodelling. Myostatin’s direct anti-osteoblastic and pro-osteoclastic effects — suppressing RUNX2-driven differentiation and increasing RANKL:OPG ratio — are antagonised by ACE-031’s ligand trapping, while activin A neutralisation addresses the additional bone-resorbing signal elevated in multiple disease contexts. Preclinical evidence in healthy animals and OVX osteoporosis models demonstrates increased BV/TV, cortical thickness and bone strength with ActRIIB-Fc treatment. Disease models where muscle and bone pathology co-occur (DMD, ALS, cancer cachexia) provide research contexts for simultaneous dual-compartment endpoint assessment. Micro-CT structural parameters, bone turnover biomarkers, histomorphometric cellular endpoints and biomechanical strength testing together constitute the standard toolkit for characterising ACE-031’s skeletal effects comprehensively. Research Use Only — UK Regulatory Notice: ACE-031 is available for purchase in the United Kingdom for research and laboratory purposes only. It is not approved for human therapeutic use, is not a licensed medicinal product, and is not intended for use in clinical practice, human self-administration or veterinary treatment without appropriate regulatory authorisation. All research applications must comply with applicable UK legislation and institutional ethical oversight requirements. 🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified ACE-031 for research and laboratory use. View UK stock → William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

Source: peptideslabuk.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

ACE-031 Dosage, Reconstitution & Mixing Trends

See ACE-031 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. ACE-031 (ramatercept) is a soluble activin receptor type IIB-Fc fusion protein engineered to act as a myostatin trap, sequestering myostatin and related TGF-beta family ligands to permit muscle hypertrophy. Acceleron Pharma advanced it into Phase 2 trials in Duchenne muscular dystrophy that were halted on safety grounds. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with ACE-031. 7 ACE-031 reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (3 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (5 sessions). The most common dosing frequency is once weekly (1 logged protocols). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Source: worldpeptideassociation.com ↗
Storage reference

Usage and Storage:

ACE-031 is supplied as a lyophilised solid to ensure maximum stability and ease of use in research environments. For best results, follow our website's detailed reconstitution and storage guidelines.

Source: uk-peptides.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →